VC
VRTX icon

Veracity Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Veracity Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,994
Closed -$888K – 262
2025
Q2 		$888K Sell
1,994
-108
-5% -$49.8K 0.3% 71
2025
Q1 		$1.02M Buy
2,102
+83
+4% +$38.7K 0.39% 54
2024
Q4 		$813K Buy
2,019
+401
+25% +$186K 0.29% 76
2024
Q3 		$752K Buy
1,618
+232
+17% +$111K 0.29% 73
2024
Q2 		$650K Sell
1,386
-30
-2% -$13K 0.27% 73
2024
Q1 		$592K Buy
1,416
+177
+14% +$74.8K 0.23% 97
2023
Q4 		$504K Buy
1,239
+54
+5% +$19.9K 0.2% 106
2023
Q3 		$412K Buy
1,185
+49
+4% +$17.1K 0.19% 112
2023
Q2 		$400K Buy
1,136
+25
+2% +$8.42K 0.17% 127
2023
Q1 		$350K Buy
1,111
+18
+2% +$5.4K 0.16% 140
2022
Q4 		$316K Buy
1,093
+76
+7% +$23.2K 0.15% 141
2022
Q3 		$294K Buy
+1,017
New +$293K 0.16% 138
2020
Q4 		– Sell
-2,180
Closed -$594K – 278
2020
Q3 		$594K Buy
2,180
+400
+22% +$110K 0.16% 154
2020
Q2 		$516K Buy
+1,780
New +$483K 0.14% 157

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Veracity Capital's VRTX Position: Q3 2025 in Review

Veracity Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,994 shares — an estimated $888K sold.

Veracity Capital first reported a position in VRTX in Q2 2020 and held it in 14 quarters. The position peaked at $1.02M in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Veracity Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Veracity Capital sold 1,994 Vertex Pharmaceuticals shares in Q3 2025, an estimated $888K.
  • Veracity Capital first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Veracity Capital's Vertex Pharmaceuticals position peaked at $1.02M in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Veracity Capital's 13F filing for Q3 2025, filed 8 Oct 2025.